Skip to content
Medical Health Aged Care

Urgent Reform Needed to Sustain Voluntary Assisted Dying Services

VADANZ (Voluntary Assisted Dying Australia & NZ) 3 mins read
Key Facts:

The 2025 VADANZ Remuneration Survey of Voluntary Assisted Dying (VAD) practitioners has revealed almost two‑thirds (63%) reported their state’s remuneration arrangements were inadequate. More than a quarter (27%) said they had provided unpaid VAD care.

 


Voluntary Assisted Dying (VAD) is now a legal end‑of‑life choice in every Australian jurisdiction except the Northern Territory. Yet despite this historic legislative shift, the financial and structural support for practitioners delivering VAD remains inadequate, threatening the sustainability of services and the wellbeing of the workforce.

The 2025 VADANZ Remuneration Survey of VAD practitioners has revealed:

  • Almost two‑thirds (63%) reported their state’s remuneration arrangements were inadequate.

  • More than a quarter (27%) said they had provided unpaid VAD care.

  • Only one‑third (32%) received any state government reimbursement.

  • All respondents in South Australia and Tasmania reported dissatisfaction, as did 80% of Victorians.

  • Queensland respondents were also largely dissatisfied (72%), particularly for rural and community-based doctors facing high travel burdens.

  • New South Wales was the only jurisdiction where a slim majority (51%) felt remuneration was adequate.

VADANZ President Dr Andrea Bendrups said VAD practitioners consistently report deep professional fulfilment in providing end-of-life care and remain strongly committed to supporting patients and their families. However Dr Bendrups noted that relying on goodwill made it difficult to maintain a stable and sustainable service over time. 

“All Australian jurisdictions, apart from the Northern Territory, have taken the courageous step of legalising VAD. Person-centered services have been established in all these jurisdictions which are delivering high quality end-of-life care, but relying on clinical altruism to do so. We urgently need to ensure those who provide this care have the support they need to continue doing so,” Dr Bendrups said. 

At present, there are no dedicated Medicare items for VAD. The Medicare Benefits Schedule (MBS) excludes “euthanasia and any service directly connected to the procedure”, leaving practitioners uncompensated for extensive non‑clinical work such as administration, portal documentation, coordination, and travel.

Survey respondents told of the ethical discomfort they felt about charging privately for VAD services. However, without proper remuneration, many privately practising GPs and specialists face financial strain. Some practitioners are questioning whether they can continue providing VAD care long term.

“We are going to extraordinary lengths to shield patients from financial burden, but the system cannot rely indefinitely on the goodwill of practitioners,” Dr Bendrups said.  

“This is not only a workforce issue, it ultimately affects patient access and continuity of care.”

Reduced practitioner participation risks limiting access to a compassionate end‑of‑life option, compromising dignity and autonomy for patients.

VADANZ is calling for several reforms, including:

  • Dedicated MBS items recognising the unique demands of VAD care.

  • Comprehensive fee schedules covering all aspects of care, including travel.

  • Increased numbers of funded hospital roles to provide stability for practitioners.

  • Clear state guidance on billing options to reduce uncertainty.

  • Federal updates to MBS Explanatory Notes to remove outdated restrictions on VAD items.

Dr Bendrups said the New Zealand model offers a proven template, with structured fee‑for‑service payments across five modules, additional remuneration for complex cases, and travel allowances. This system ensures transparency and fairness, principles that underpin a sustainable system. 

“Without adequate remuneration, the system risks collapsing under the weight of unpaid labour and practitioner burnout,’’ Dr Bendrups said.

“We look forward to working constructively with policymakers to align funding structures with the realities of VAD practice.”

Read the survey

NOTES: 

The survey of VADANZ members was conducted from 16 April to 24 July, 2025. 

There were 170 respondents, representing 12% of the national workforce. Among them, 42% were general practitioners (GPs) and 45% were other specialists. The vast majority had more than 11 years’ clinical experience. 

The survey does not include the Northern Territory or the ACT because there was no VAD legislation in effect in either jurisdiction at the time the survey was conducted.

 


About us:

Voluntary Assisted Dying Australia and New Zealand (VADANZ) is the peak body for health professionals providing voluntary assisted dying (VAD) care.

 


Contact details:

Dr Andrea Bendrups, VADANZ president.

[email protected] 

Media

More from this category

  • Business Company News, Medical Health Aged Care
  • 27/01/2026
  • 12:44
Nova Eye Medical (ASX:EYE)

Nova Eye Medical’s iTrack(TM) Registry Clinical Data Show Positive Outcomes

Highlights Annual statistical report on progress of patients in theiTrack™ Global Data Registry (iTrack™ Registry) was released this month 409 eyes, followed for 12…

  • Contains:
  • Medical Health Aged Care
  • 27/01/2026
  • 12:06
The Australian Nursing and Midwifery Federation (ANMF)

ANMF condemns fatal shooting of US intensive care nurse

The Australian Nursing and Midwifery Federation (ANMF) has expressed its deep shock and sorrow at the fatal shooting of intensive care nurse Alex Pretti, during an incident involving ICE agents in Minneapolis. The ANMF stands with our colleagues across borders in condemning the shooting of Mr Pretti and has called for accountability,transparency and justice in ensuring that his tragic death is properly and independently investigated by US authorities. Nurses around the world dedicate their lives to caring for others in their communities. The violent death of a registered nurse is an intolerable breach of the fundamental respect and dignity owed…

  • Finance Investment, Medical Health Aged Care
  • 27/01/2026
  • 10:13
Jane Morgan Management

Nexsen secures $500,000 Federal grant to expand rapid GBS diagnostics into neonatal care

27 January 2026 – Melbourne, Australia | Nexsen Limited (ASX:NXN) has secured a $500,000 non-dilutive Federal Government grant to expand its rapid point-of-care diagnostic platform into neonatal testing, significantly broadening the commercial and clinical scope of its Group B Streptococcus (GBS) program for a materially larger opportunity for testing. The funding has been awarded to RMIT University under the Commonwealth’s Australia’s Economic Accelerator (AEA) Ignite program, with Nexsen appointed as the industry commercialisation partner. The project, titled “Transforming Neonatal Care with a Rapid Diagnostic for Group B Streptococcus (GBS)”, has a total value exceeding $1 million. The initiative will support…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.